Mindful Care adds brain-biology testing to antidepressant prescribing

Mindful Care is partnering with NeuroKaire to offer BrightKaire, a blood-based test that helps clinicians match patients to antidepressants using their own brain-cell response. The test will be available through Mindful Care’s hybrid telehealth and clinic model across six states, aiming to reduce trial-and-error prescribing.

Why it matters: - Depression treatment often still relies on trial and error, and only about a third of patients respond to the first antidepressant they try. - Each medication switch can take six to 12 weeks, which can delay relief for patients seeking faster mental health care. - The partnership gives Mindful Care a way to add biology-based prescribing to same-day and next-day psychiatric visits.

What happened: - Mindful Care is partnering with precision psychiatry company NeuroKaire to bring BrightKaire into routine care. - The test will be available through Mindful Care’s hybrid telemedicine and in-person workflow. - Patients in Connecticut, Florida, Illinois, Michigan, New Jersey and New York can ask whether BrightKaire is right for them at their next visit. - Mindful Care says it is the first hybrid telehealth provider to offer BrightKaire as part of its services.

The details: - BrightKaire uses a blood draw to create a personalized “brain in a dish.” - The test relies on stem cell technology to convert a patient’s blood sample into frontal cortex neurons. - Those neurons are exposed to a panel of commonly prescribed antidepressants to measure response. - The report is delivered to both the patient and clinician to guide treatment decisions before a prescription is chosen. - Patients can book a same-day or next-day virtual or in-person appointment with Mindful Care. - Clinicians can order the blood-based diagnostic during the same visit. - Patients can get blood drawn within days at a Quest lab or at home with a phlebotomist. - Mindful Care operates in six states and is licensed in 14. - Mindful Care provides urgent mental health care, psychiatric care, therapy and addiction recovery services for people ages 12 and up. - Mindful Care accepts most major insurance, including Medicare and Medicaid.

Between the lines: - The deal extends precision psychiatry beyond specialty psychiatric clinics and into a broader telehealth platform. - NeuroKaire is betting that access, not just science, is the main barrier to personalized antidepressant selection. - Mindful Care is trying to keep its same-day care model while adding a more detailed way to choose medications. - The move reflects growing demand for telehealth mental health care, which has become the largest category of telehealth in the U.S.

What's next: - Patients can begin discussing BrightKaire with their Mindful Care provider at the next visit. - The companies are positioning the test as a faster path to the right antidepressant and fewer medication trials. - NeuroKaire also said its approach could support broader precision medicine use in psychiatry and neurology.

The bottom line: - Mindful Care is adding a biological layer to antidepressant prescribing, pushing telehealth mental health care closer to personalized medicine.